Cargando…

Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer : Comparative Analysis between 1st-line and 2nd-line Docetaxel

PURPOSE: This study was undertaken to investigate the outcomes associated with docetaxel treatment of Korean patients with hormone-refractory prostate cancer (HRPC) and to compare its clinical efficacies in 1st and 2nd-line settings. MATERIALS AND METHODS: This study was retrospectively performed an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Joung, Jae Young, Jeong, In Gab, Han, Kyung Seok, Kim, Taek Sang, Yang, Seung Ok, Seo, Ho Kyung, Chung, Jinsoo, Cho, Kang Su, Lee, Kang Hyun
Formato:	Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2008
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2615369/ https://www.ncbi.nlm.nih.gov/pubmed/18972598 http://dx.doi.org/10.3349/ymj.2008.49.5.775

Ejemplares similares

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer
por: Vasey, P A, et al.
Publicado: (2001)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
por: Kwon, Whi-An, et al.
Publicado: (2019)

Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
por: Lee, Min Jeong, et al.
Publicado: (2012)

Nail Changes During Docetaxel Containing Combination Chemotherapy
por: Woo, In Sook, et al.
Publicado: (2004)

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
por: Sinibaldi, Victoria J
Publicado: (2007)

Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema
por: Lim, Hyun-Kyung, et al.
Publicado: (2016)

Combination Effects of Docetaxel and Doxorubicin in Hormone-Refractory Prostate Cancer Cells
por: Tsakalozou, Eleftheria, et al.
Publicado: (2012)

Tryptophanyl-tRNA Synthetase Sensitizes Hormone Receptor-Positive Breast Cancer to Docetaxel-Based Chemotherapy
por: Lee, Kyung-Min, et al.
Publicado: (2020)

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
por: Lee, Ha-young, et al.
Publicado: (2012)

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
por: Clamp, A R, et al.
Publicado: (2006)

Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study
por: Li, Jinyu, et al.
Publicado: (2015)

The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma
por: Choi, Jong Hyun, et al.
Publicado: (2019)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
por: Calcagno, Fabien, et al.
Publicado: (2012)

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
por: Vasey, P A, et al.
Publicado: (2002)

Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
por: O'Neill, Amanda J, et al.
Publicado: (2011)

Grover disease associated with docetaxel chemotherapy
por: Afvari, Shawn, et al.
Publicado: (2022)

Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles
por: Kramer, G, et al.
Publicado: (2006)

Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
por: Ko, Yoon Ho, et al.
Publicado: (2007)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
por: Naiki, Taku, et al.
Publicado: (2018)

Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer
por: Kubota, Hiroki, et al.
Publicado: (2017)

Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma
por: Song, Zhengbo, et al.
Publicado: (2014)

Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer
por: Galli, L, et al.
Publicado: (2007)

A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
por: Lee, Keun-Wook, et al.
Publicado: (2017)

A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer
por: Collins, R, et al.
Publicado: (2006)

Transcriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy
por: Schmitt, Esther, et al.
Publicado: (2015)

Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy
por: Zhang, Sheng, et al.
Publicado: (2015)

Predictive Factors for Premature Discontinuation of Docetaxel-Based Systemic Chemotherapy in Men With Castration-Resistant Prostate Cancer
por: Park, Seung Chol, et al.
Publicado: (2013)

A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy
por: Won, Young-Woong, et al.
Publicado: (2023)

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
por: Gamucci, T, et al.
Publicado: (2007)

Establishment and characterization of a docetaxel-resistant human prostate cancer cell line
por: Liu, Jian, et al.
Publicado: (2020)

Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1
por: Jung, Joo Young, et al.
Publicado: (2016)

Docetaxel–induced syndrome of inappropriate antidiuretic hormone secretion
por: Chaudhuri, Tamojit, et al.
Publicado: (2013)

A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma
por: Seddon, Beatrice, et al.
Publicado: (2015)

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
por: Hilkens, P. H., et al.
Publicado: (1997)

Clinical predictor of survival following docetaxel-based chemotherapy
por: LEE, HSIANG-YING, et al.
Publicado: (2014)

Trastuzumab–Docetaxel Combination Chemotherapy Induced Severe Onychopathy
por: Sonthalia, Sidharth, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_nc49vusocadb1o8ugcme217064